Erschienen in:
01.12.2014 | Prevention of Heart Failure (M St. John Sutton, Section Editor)
Epidemiology of Heart Failure with Preserved Ejection Fraction
verfasst von:
Abhinav Dhingra, Aayushi Garg, Simrat Kaur, Saurav Chopra, Jaspreet Singh Batra, Ambarish Pandey, Antoine H. Chaanine, Sunil K. Agarwal
Erschienen in:
Current Heart Failure Reports
|
Ausgabe 4/2014
Einloggen, um Zugang zu erhalten
Abstract
The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.